Safety assessment and potential risks of tofacitinib

Although Tofacitinib (Tofacitinib), as a JAK inhibitor with strong targeting and clear mechanism, has achieved good results in the treatment of chronic inflammatory diseases such as rheumatoid arthritis , psoriatic arthritis, ulcerative colitis, etc., its safety issues have also attracted widespread clinical attention. According to data provided by its manufacturer Pfizer (Pfizer) and multiple clinical monitoring results released by drug regulatory agencies such as the US FDA and EMA, the potential risks of tofacitinib include infection, cardiovascular events, malignant tumors and blood abnormalities.

The most important safety signal comes from a large clinical study calledORAL Surveillance, a randomized controlled trial conducted in patients with rheumatoid arthritis over 50 years old and with at least one cardiovascular risk factor. The purpose was to compare the safety of tofacitinib with two TNF inhibitors (adalimumab and etanercept). The results showed that the incidence of major adverse cardiovascular events (MACE) and certain types of cancer, especially lung cancer and lymphoma, were significantly higher in the tofacitinib group. In addition, tofacitinib has been observed to increase the risk of deep vein thrombosis and pulmonary embolism, especially at high doses (10 mg BID).

In addition to cardiovascular and tumor risks, infection risk is also a key assessment indicator. SinceJAK inhibitors affect multiple immune factor pathways, tofacitinib users are more likely to develop serious infections (such as pneumonia, tuberculosis, herpes zoster) than the general population, especially when combined with glucocorticoids or other immunosuppressants, the risk is higher. In addition, long-term use may also lead to abnormal laboratory indicators such as elevated blood lipids, abnormal liver enzymes, and leukopenia. Therefore, regular monitoring is required during use, including CBC, liver function, and blood lipid levels.

Reference materials:https://www.xeljanz.com/